GH Research PLC
GHRS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001855129
No open-market purchases or sales by GH Research PLC insiders were filed in the last 90 days; 63 institutions reported holding it in 13F filings for Q2 2026, worth $1.38B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +9 vs. previous quarter
- 63
- 13F valueReported value at the end of Q2 2026
- $1.38B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding GHRS, Q2 2026
No superinvestor reported holding GHRS at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by GH Research PLC insiders from Form 4, newest first.
No open-market purchases or sales by GH Research PLC insiders are on file.
Top 10 13F holders, Q2 2026
The largest institutional positions in GH Research PLC at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Lynx1 Capital Management LP | 13,263,288 | $356.5M | 41.19% | +2,500,000+23.2% | Added |
| BVF Inc | 8,650,158 | $232.5M | 5.95% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 7,636,813 | $205.3M | 1.78% | −39,884−0.5% | Reduced |
| FMR LLC | 5,977,045 | $160.7M | 0.01% | +841,000+16.4% | Added |
| RTW Investments, LP | 5,933,815 | $159.5M | 1.36% | 00.0% | Unchanged |
| Deep Track Capital, LP | 3,333,334 | $89.6M | 1.32% | +3,333,334 | New |
| Avoro Capital Advisors LLC | 1,800,000 | $48.4M | 0.43% | 00.0% | Unchanged |
| Foresite Capital Management VI LLC | 940,493 | $25.3M | 3.93% | +625,001+198.1% | Added |
| Jefferies Financial Group Inc. | 712,300 | $19.1M | 0.18% | 00.0% | Unchanged |
| BlackRock, Inc. | 480,287 | $12.9M | 0.00% | +24,669+5.4% | Added |